CELL RECEPTOR DEVELOPS A FUTURE-ORIENTED THERAPY FOR HIGH MEDICAL NEEDS: CANCER AND AUTOIMMUNE DISEASES
Cell Receptor is a small Geneva-based corporation that is building new treatments to prevent cancer metastasis and control autoimmune diseases:
Cell Receptor's team is active in research on cell proliferation regulation processes and is investigating a very basic mechanism of cell division control in our body. Until now, this was little known and has therefore hardly been the subject of therapeutic efforts. The focus here is on transport mechanisms of signalling substances for the control of cell growth and immune response.
Cell Receptor also has insights into pharmacologically applicable substances that can modulate these mechanisms. Based on this, a method has been developed for the broad prevention of cancer metastases and the suppression of undesired proliferative processes, for example in the immune system. The company owns significant intellectual property for this. Our patents relate to the blockade of the transport process by means of kind substances, which we have recognised as effective and which have been confirmed by the results of independent research groups. We are convinced that the clinical demand will be quite substantial.
Cell Receptor is looking for suitable cooperations and is also projecting a clinical trial in cooperation with a renowned hospital as proof of its concept. Here, in the sense of repurposing, a substance recognised by us as effective and already approved will be used.